FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309492367> ?p ?o ?g. }

• W4309492367 abstract "Background Antidepressants may be useful in the treatment of abnormal crying associated with stroke. This is an update of a Cochrane Review first published in 2004 and last updated in 2019. Objectives To evaluate the benefits and harms of pharmaceutical treatment in people with emotionalism after stroke. Search methods We searched the Cochrane Stroke Group Register, CENTRAL, MEDLINE, Embase, four other databases, and three trials registers (May 2022). Selection criteria We included randomised controlled trials (RCTs) and quasi‐RCTs comparing psychotropic medication to placebo in people with stroke and emotionalism (also known as emotional lability, pathological crying or laughing, emotional incontinence, involuntary emotional expression disorder, and pseudobulbar affect). Data collection and analysis Two review authors independently selected trials, assessed risk of bias, extracted data from all included trials, and used GRADE to assess the certainty of the body of evidence. We calculated the mean difference (MD) or standardised mean difference (SMD) for continuous data and the risk ratio (RR) for dichotomous data, with 95% confidence intervals (CIs). We assessed heterogeneity using the I2 statistic. The primary emotionalism measures were the proportion of participants achieving at least a 50% reduction in abnormal emotional behaviour at the end of treatment, improved score on the Center for Neurologic Study ‐ Lability Scale (CNS‐LS) or Clinician Interview‐Based Impression of Change (CIBIC), or diminished tearfulness. Main results We did not identify any new trials for this update. We included seven trials with a total of 239 participants. Two trials had a cross‐over design, but outcome data were not available from the first phase (precross‐over) in an appropriate format for inclusion as a parallel randomised controlled trial (RCT). Thus, the results of the review are based on five trials with a total of 213 participants. It is uncertain whether fluoxetine increases the number of people who have a 50% reduction in emotionalism when compared to placebo (risk ratio (RR) 0.26, 95% CI 0.09 to 0.77; P = 0.02; 1 trial, 19 participants) because the certainty of evidence is very low. Sertraline may lead to little to no difference in Center for Neurologic Study ‐ Lability Scale (CNS‐LS) scores and Clinician Interview‐Based Impression of Change (CIBIC) scores when compared to placebo (RR 0.20, 95% CI 0.03 to 1.50; P = 0.12; 1 trial, 28 participants; low‐certainty evidence). Antidepressants probably increase the number of people who experience a reduction in tearfulness (RR 0.32, 95% CI 0.12 to 0.86; P = 0.02; 3 trials, 164 participants; moderate‐certainty evidence). No trials were found that evaluated the impact of other pharmaceutical interventions. Only two trial authors systematically recorded and reported adverse events, resulting in limited data on the potential harms of treatment. Six trials reported death as an adverse event and found no difference between the groups (antidepressants versus placebo) in the number of deaths reported (RR 0.59, 95% CI 0.08 to 4.50; P = 0.61; 172 participants; moderate‐certainty evidence). This review provides very low‐ to moderate‐certainty evidence that antidepressants may reduce the frequency and severity of emotionalism. The included trials were small and had some degree of bias. Authors' conclusions Antidepressants may reduce the frequency and severity of crying or laughing episodes when compared to placebo, based on very low‐certainty evidence. Our conclusions must be qualified by several methodological deficiencies in the trials and interpreted with caution despite the effect being very large. The effect does not seem specific to one drug or class of drugs. More reliable data are required before appropriate conclusions can be made about the treatment of post‐stroke emotionalism. Future trialists investigating the effect of antidepressants in people with emotionalism after stroke should consider developing and using a standardised method to diagnose emotionalism, determine severity, and assess change over time; provide treatment for a sufficient duration and follow‐up to better assess rates of relapse or maintenance; and include careful assessment and complete reporting of adverse events." @default.
• W4309492367 created "2022-11-28" @default.
• W4309492367 creator A5004304374 @default.
• W4309492367 creator A5006770351 @default.
• W4309492367 creator A5029135852 @default.
• W4309492367 date "2022-11-17" @default.
• W4309492367 modified "2023-10-17" @default.
• W4309492367 title "Pharmaceutical interventions for emotionalism after stroke" @default.
• W4309492367 cites W1598577731 @default.
• W4309492367 cites W1689011551 @default.
• W4309492367 cites W1813312189 @default.
• W4309492367 cites W1845447069 @default.
• W4309492367 cites W1847168837 @default.
• W4309492367 cites W1971065093 @default.
• W4309492367 cites W1973002186 @default.
• W4309492367 cites W1973017097 @default.
• W4309492367 cites W1973986281 @default.
• W4309492367 cites W1974540211 @default.
• W4309492367 cites W1982474265 @default.
• W4309492367 cites W1987358702 @default.
• W4309492367 cites W1988811691 @default.
• W4309492367 cites W2007566314 @default.
• W4309492367 cites W2008835455 @default.
• W4309492367 cites W2008854521 @default.
• W4309492367 cites W2011647040 @default.
• W4309492367 cites W2014360157 @default.
• W4309492367 cites W2018930912 @default.
• W4309492367 cites W2022625597 @default.
• W4309492367 cites W2025945437 @default.
• W4309492367 cites W2026525039 @default.
• W4309492367 cites W2027441036 @default.
• W4309492367 cites W2030005246 @default.
• W4309492367 cites W2032738024 @default.
• W4309492367 cites W2037569408 @default.
• W4309492367 cites W2041852850 @default.
• W4309492367 cites W2051778264 @default.
• W4309492367 cites W2058161128 @default.
• W4309492367 cites W2058444479 @default.
• W4309492367 cites W2058593695 @default.
• W4309492367 cites W2064711426 @default.
• W4309492367 cites W2067495470 @default.
• W4309492367 cites W2073494396 @default.
• W4309492367 cites W2074655548 @default.
• W4309492367 cites W2077965891 @default.
• W4309492367 cites W2078270682 @default.
• W4309492367 cites W2079397098 @default.
• W4309492367 cites W2084335051 @default.
• W4309492367 cites W2088853707 @default.
• W4309492367 cites W2103994810 @default.
• W4309492367 cites W2109349376 @default.
• W4309492367 cites W2114613490 @default.
• W4309492367 cites W2131823335 @default.
• W4309492367 cites W2134940169 @default.
• W4309492367 cites W2137103253 @default.
• W4309492367 cites W2138145169 @default.
• W4309492367 cites W2148080316 @default.
• W4309492367 cites W2150611178 @default.
• W4309492367 cites W2154415122 @default.
• W4309492367 cites W2158905832 @default.
• W4309492367 cites W2166281097 @default.
• W4309492367 cites W2166859869 @default.
• W4309492367 cites W2167311298 @default.
• W4309492367 cites W2169044294 @default.
• W4309492367 cites W2178627879 @default.
• W4309492367 cites W2228872415 @default.
• W4309492367 cites W2312252809 @default.
• W4309492367 cites W2317571929 @default.
• W4309492367 cites W2318816678 @default.
• W4309492367 cites W2338557036 @default.
• W4309492367 cites W2405498557 @default.
• W4309492367 cites W2419059555 @default.
• W4309492367 cites W2567245668 @default.
• W4309492367 cites W2596044727 @default.
• W4309492367 cites W2737966001 @default.
• W4309492367 cites W2748226891 @default.
• W4309492367 cites W2766372244 @default.
• W4309492367 cites W2768689142 @default.
• W4309492367 cites W2774452660 @default.
• W4309492367 cites W2946933758 @default.
• W4309492367 cites W2946946391 @default.
• W4309492367 cites W3026143908 @default.
• W4309492367 cites W3116594058 @default.
• W4309492367 cites W3118615836 @default.
• W4309492367 cites W3170711544 @default.
• W4309492367 cites W3212371888 @default.
• W4309492367 cites W4220798688 @default.
• W4309492367 cites W4250562307 @default.
• W4309492367 cites W53719984 @default.
• W4309492367 doi "https://doi.org/10.1002/14651858.cd003690.pub5" @default.
• W4309492367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36394565" @default.
• W4309492367 hasPublicationYear "2022" @default.
• W4309492367 type Work @default.
• W4309492367 citedByCount "2" @default.
• W4309492367 countsByYear W43094923672023 @default.
• W4309492367 crossrefType "journal-article" @default.
• W4309492367 hasAuthorship W4309492367A5004304374 @default.
• W4309492367 hasAuthorship W4309492367A5006770351 @default.
• W4309492367 hasAuthorship W4309492367A5029135852 @default.
• W4309492367 hasBestOaLocation W43094923672 @default.
• W4309492367 hasConcept C118552586 @default.

• next